All Title Author
Keywords Abstract

Ocriplasmin for Vitreoretinal Diseases

DOI: 10.1155/2012/354979

Full-Text   Cite this paper   Add to My Lib


Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.


comments powered by Disqus

Contact Us


微信:OALib Journal